Ocuphire Pharma has commenced its Phase 3 VEGA-3 clinical trial (NCT06542497) to investigate phentolamine ophthalmic solution 0.75% as a potential treatment for presbyopia. The first patient has been dosed, marking a significant step in the development of a non-invasive option for individuals with age-related near vision loss.
Phentolamine ophthalmic solution 0.75% is designed to offer a convenient alternative to traditional corrective measures like reading glasses or surgery. Presbyopia, a common age-related condition, affects a large portion of the population, leading to a decreased ability to focus on near objects. The current treatment landscape primarily involves corrective lenses, but a non-invasive pharmaceutical option could address a significant unmet need.
The VEGA-3 trial is a Phase 3 study designed to evaluate the efficacy and safety of phentolamine ophthalmic solution 0.75%. The trial will assess the change in near visual acuity in patients with presbyopia following administration of the eye drops. Further details about the trial design, patient population, and specific endpoints were not disclosed in the announcement. Ocuphire Pharma's press release indicates that phentolamine ophthalmic solution 0.75% aims to provide a convenient and effective solution for presbyopia, potentially improving the quality of life for millions affected by this condition.
